The Research Peptide Market Has a Quality Problem

The peptide market has exploded in recent years, driven by clinical breakthroughs in GLP-1 agonists and growing interest in research compounds like BPC-157 and TB-500. But with growth comes opportunism — and the unregulated nature of the research peptide market means quality varies wildly.

Here are five red flags that should make you walk away from a vendor.

Red Flag #1: No Certificates of Analysis

If a vendor can’t provide a Certificate of Analysis for every batch, walk away. Legitimate COAs include HPLC purity data and mass spectrometry confirmation from a third-party lab — not a PDF they made in Canva.

Red Flag #2: Health Claims

Any vendor claiming their peptides “cure,” “treat,” or “heal” anything is violating FDA regulations. Research peptides are for in-vitro laboratory use only. Vendors who market to consumers with health promises are one FDA warning letter away from shutting down — and taking your order with them.

Red Flag #3: No CAS Numbers or Molecular Data

A vendor that doesn’t list CAS numbers, molecular formulas, or molecular weights either doesn’t know their products or doesn’t want you to verify them. Both are bad. Every compound has a unique CAS registry number — it takes 30 seconds to list it.

Red Flag #4: Prices That Are Too Good

If a vendor sells 10mg of BPC-157 for $15 when the market average is $40-55, they’re either selling underdosed product, impure material, or something else entirely. Quality peptide synthesis costs money. Suspiciously low prices are a signal, not a deal.

Red Flag #5: No Physical Presence

Check for a real business address, contact information, and legal pages (Terms of Service, Privacy Policy, Refund Policy). Anonymous vendors with nothing but a Telegram handle are not suppliers — they’re risks.

What Good Looks Like

MedTides was built to be the vendor we wished existed — transparent, fairly priced, and compliant. Browse our full catalog at medtides.us/products.

Sources

  1. U.S. Food and Drug Administration (2023). "Dietary Supplements: FDA Warning Letters." fda.gov
  2. National Institutes of Health. "PubChem Compound Database." pubchem.ncbi.nlm.nih.gov
← Back to Blog